Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Those who received the NAC saw an overall improvement compared to those who were given a placebo
1 : 88100 Cullis PR, DeKruijff B
The work was supported by the Monash University Ramaciotti Centre for Cryo-Electron Microscopy, the Bio21 Ian Holmes Imaging Centre (The University of Melbourne) and the Monash eResearch capabilities, including M3 High-performance computing
SAGE Open Med 9:20503121211034366 Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I et al (2023) Randomized, Double-Blind, Placebo-Controlled, global phase III trial of talimogene Laherparepvec combined with pembrolizumab for advanced melanoma
A clinical trial studies a drug under strict research rules
GLP-1 agonists were initially approved for treating type 2 diabetes, with subsequent approvals for chronic weight management and reduction of the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 diabetes
